ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,292,431 | -29.2% | 308,613 | -6.0% | 0.00% | -33.3% |
| Q2 2023 | $11,710,494 | +47459.2% | 328,393 | -66.1% | 0.01% | -57.1% |
| Q1 2023 | $24,623 | +5.5% | 969,394 | +68.4% | 0.01% | +7.7% |
| Q4 2022 | $23,347 | -99.1% | 575,624 | +631.3% | 0.01% | +550.0% |
| Q3 2022 | $2,601,000 | -46.1% | 78,714 | -42.6% | 0.00% | -33.3% |
| Q2 2022 | $4,830,000 | -24.7% | 137,178 | -1.7% | 0.00% | 0.0% |
| Q1 2022 | $6,415,000 | +215.7% | 139,480 | +355.0% | 0.00% | +200.0% |
| Q4 2021 | $2,032,000 | -32.2% | 30,656 | -36.2% | 0.00% | -50.0% |
| Q3 2021 | $2,998,000 | -33.0% | 48,019 | -11.1% | 0.00% | -33.3% |
| Q2 2021 | $4,474,000 | +124.0% | 54,031 | +79.4% | 0.00% | +200.0% |
| Q1 2021 | $1,997,000 | -58.0% | 30,119 | -51.4% | 0.00% | -75.0% |
| Q4 2020 | $4,760,000 | -41.3% | 62,029 | -67.0% | 0.00% | -60.0% |
| Q3 2020 | $8,106,000 | +275.3% | 188,244 | +276.5% | 0.01% | +233.3% |
| Q2 2020 | $2,160,000 | -90.9% | 50,000 | -86.7% | 0.00% | -90.0% |
| Q4 2019 | $23,841,000 | +130.0% | 375,857 | +2.2% | 0.03% | +87.5% |
| Q3 2019 | $10,365,000 | -19.9% | 367,856 | -24.7% | 0.02% | -15.8% |
| Q2 2019 | $12,940,000 | -25.3% | 488,289 | -48.3% | 0.02% | -26.9% |
| Q1 2019 | $17,319,000 | +1204.1% | 943,835 | +782.6% | 0.03% | +1200.0% |
| Q4 2018 | $1,328,000 | -74.5% | 106,941 | -60.7% | 0.00% | -66.7% |
| Q3 2018 | $5,215,000 | -11.5% | 272,061 | -66.7% | 0.01% | -25.0% |
| Q1 2018 | $5,893,000 | +57.6% | 817,317 | -19.6% | 0.01% | +60.0% |
| Q4 2017 | $3,740,000 | -32.1% | 1,016,427 | -20.1% | 0.01% | -37.5% |
| Q3 2017 | $5,508,000 | +130.2% | 1,272,138 | -13.9% | 0.01% | +100.0% |
| Q2 2017 | $2,393,000 | +167.1% | 1,477,039 | +205.0% | 0.00% | +100.0% |
| Q1 2017 | $896,000 | -50.9% | 484,330 | -58.9% | 0.00% | -50.0% |
| Q4 2016 | $1,825,000 | +638.9% | 1,177,293 | +3401.8% | 0.00% | – |
| Q3 2016 | $247,000 | +57.3% | 33,620 | +13.9% | 0.00% | – |
| Q2 2016 | $157,000 | – | 29,511 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |